| Literature DB >> 33799887 |
Ewa Tomaszewska1, Siemowit Muszyński2, Anna Arczewska-Włosek3, Piotr Domaradzki4, Renata Pyz-Łukasik5, Janine Donaldson6, Sylwester Świątkiewicz3.
Abstract
The current study aimed to assess the effects of dietary alpha-ketoglutarate (AKG) supplementation to laying hens on the fatty acid (FA) profile and cholesterol levels of the egg yolk at the end of production cycle. The experiment was performed on forty-eight Bovans Brown laying hens randomly assigned to either a control group (CONT) or a group supplemented with AKG. The CONT group was fed the basal diet, and the AKG group was fed the basal diet plus 1.0% AKG from the 31st until the 60th week of age, when FA profile, fat and cholesterol content of the egg yolks were determined. No significant changes in the cholesterol and total fat content of the egg yolks were observed. However, there were positive (the decrease in n-6 FA and the increase in MUFA), and negative (decrease in PUFA and n-3 FA, increase in TI and n-6/n-3 ratio) changes in FA profile following AKG supplementation. In conclusion, it was shown that dietary AKG after a 30-week long supplementation influence FA profile in egg yolk and its nutritional value.Entities:
Keywords: alpha-ketoglutarate; cholesterol; egg yolk; fatty acids
Year: 2021 PMID: 33799887 PMCID: PMC8001726 DOI: 10.3390/foods10030596
Source DB: PubMed Journal: Foods ISSN: 2304-8158
The effect of dietary AKG supplementation to laying hens during a 30-week experimental period (31st–60th week of age) on egg yolk total fat, cholesterol content (%), yolk fatty acid composition (% of total fatty acids) and health lipid indices determined at the end of study.
| Item | Control | AKG | |
|---|---|---|---|
| Total fat content, % | 28.64 ± 0.13 | 28.46 ± 0.06 | 0.238 |
| Total cholesterol, mg/g of yolk | 11.73 ± 0.17 | 11.59 ± 0.11 | 0.471 |
| Fatty acids | |||
| C14:0 | 0.36 ± 0.02 | 0.37 ± 0.01 | 0.977 |
| C16:0 | 24.55 ± 0.14 | 24.99 ± 0.23 | 0.126 |
| C18:0 | 6.92 ± 0.06 | 7.01 ± 0.08 | 0.751 |
| Σ SFA | 31.89 ± 0.17 | 32.37 ± 0.19 | 0.073 |
| C15:0 | 0.06 ± 0.01 | 0.06 ± 0.01 | 0.757 |
| C17:0 | 0.18 ± 0.01 | 0.19 ± 0.02 | 0.501 |
| Σ OCFA | 0.24 ± 0.01 | 0.25 ± 0.02 | 0.627 |
| C14:1c9 | 0.07 ± 0.01 | 0.08 ± 0.01 | 0.021 |
| C15:1 | 0.09 ± 0.01 | 0.08 ± 0.01 | 0.016 |
| C16:1c7 | 0.91 ± 0.03 | 0.97 ± 0.03 | 0.207 |
| C16:1c9 | 2.98 ± 0.08 | 3.39 ± 0.08 | 0.001 |
| C17:1c9 | 0.21 ± 0.01 | 0.18 ± 0.01 | 0.042 |
| C18:1c9 | 44.49 ± 0.33 | 46.16 ± 0.27 | <0.001 |
| C18:1c11 | 2.24 ± 0.04 | 2.44 ± 0.03 | <0.001 |
| C20:1c11 | 0.22 ± 0.01 | 0.20 ± 0.01 | 0.029 |
| Σ MUFA cis | 51.23 ± 0.26 | 53.50 ± 0.29 | <0.001 |
| C18:2n-6 | 11.67 ± 0.26 | 9.69 ± 0.18 | <0.001 |
| C18:3n-6 | 0.09 ± 0.01 | 0.07 ± 0.01 | 0.008 |
| C20:2n-6 | 0.08 ± 0.01 | 0.07 ± 0.01 | 0.047 |
| C20:3n-6 | 0.13 ± 0.01 | 0.11 ± 0.01 | 0.069 |
| C20:4n-6 | 1.73 ± 0.03 | 1.56 ± 0.01 | <0.001 |
| C22:4n-6 | 0.14 ± 0.01 | 0.11 ± 0.01 | <0.001 |
| C22:5n-6 | 0.23 ± 0.02 | 0.23 ± 0.01 | 0.751 |
| Σ PUFA n-6 | 14.04 ± 0.27 | 11.84 ± 0.15 | <0.001 |
| C18:3n-3 | 0.91 ± 0.03 | 0.59 ± 0.01 | <0.001 |
| C22:5n-3 | 0.15 ± 0.01 | 0.12 ± 0.01 | 0.002 |
| C22:6n-3 | 1.44 ± 0.03 | 1.17 ± 0.01 | <0.001 |
| Σ PUFA n-3 | 2.50 ± 0.06 | 1.87 ± 0.02 | <0.001 |
| Σ PUFA | 16.55 ± 0.27 | 13.71 ± 0.23 | <0.001 |
| Σ LC-PUFA | 3.91 ± 0.07 | 3.36 ± 0.02 | <0.001 |
| Σ LC n-6 | 2.31 ± 0.05 | 2.08 ± 0.02 | <0.001 |
| Σ LC n-3 | 1.59 ± 0.03 | 1.29 ± 0.01 | <0.001 |
| Σ MUFA trans | 0.08 ± 0.01 | 0.15 ± 0.01 | <0.001 |
| PUFA n-6/n-3 | 5.65 ± 0.12 | 6.32 ± 0.06 | <0.001 |
| PUFA/SFA | 0.52 ± 0.01 | 0.42 ± 0.01 | <0.001 |
| S/P | 0.47 ± 0.01 | 0.48 ± 0.01 | 0.022 |
| TI | 0.79 ± 0.01 | 0.84 ± 0.01 | <0.001 |
| AI | 0.38 ± 0.01 | 0.39 ± 0.01 | 0.062 |
| h/H | 2.44 ± 0.03 | 2.35 ± 0.03 | 0.036 |
| NV | 0.44 ± 0.01 | 0.45 ± 0.01 | 0.156 |
Values are expressed as the mean ± SEM from n = 12 samples per each group. Only FA with mean content ≥ 0.05% are specified. Presented Σ of particular group of FA also included FA < 0.05%. SFA—saturated fatty acids, OCFA—odd-chain fatty acids, MUFA—monosaturated fatty acids, PUFA—polyunsaturated fatty acids, LC-PUFA—long chain polyunsaturated fatty acids, S/P—saturation index, TI—thrombogenic index, AI—atherogenicity index, h/H—hypocholesterolaemic/hypercholesterolaemic ratio, NV—nutritional value.
Figure 1Results of the principal component analysis (PCA) for partial sums of fatty acids (Σ SFA, Σ MUFA, Σ PUFA, Σ n-3, Σ n-6) of the yolk of eggs obtained from hens in the control group and from hens supplemented with 1.0% AKG during a 30-week experimental period (31st–60th week of age), determined at the end of study. (A) Correlation between all the original variables included in the PCA of the first two principal components (PC). Correlations greater than 0.5 (absolute value) are considered significant. (B) PCA bi-plot (loading plot) for the PC1 and PC2 components.
Nutritional contribution of the egg yolk in terms of total fat, fatty acid content and cholesterol content to the adult diet, considering the consumption of mean-sized eggs from the control (mean egg yolk weight: 16.6 g) and AKG-supplemented (mean egg yolk weight: 17.4 g) hens.
| Specification | Percent (%) of Energy Requirements Recommended by FAO 1 | g/Day (for a 2000 Kcal Diet) 2 | Mean Content (g) in Egg Yolk | Percent (%) of Contribution for a 2000 Kcal Diet | ||
|---|---|---|---|---|---|---|
| Control | AKG | Control | AKG | |||
| Total fat | 20.0–35.0 | 44.0–78.0 | 4.77 | 4.95 | 6.1–10.8 | 6.3–11.3 |
| Σ SFA | <10.0 | <22.0 | 1.26 | 1.33 | ≥5.7 | ≥6.0 |
| Σ MUFA | 15.0–20.0 | 33.0–44.0 | 2.03 | 2.21 | 4.6–6.2 | 5.0–6.7 |
| Σ PUFA | 6.0–11.0 | 13.0–24.0 | 0.66 | 0.56 | 2.7–5.0 | 2.3–4.3 |
| Σ n-6 | 2.5–9.0 | 5.6–20.0 | 0.56 | 0.49 | 2.8–9.9 | 2.4–8.7 |
| Σ n-3 | 0.5–2.0 | 1.1–4.4 | 0.099 | 0.077 | 2.2–9.0 | 1.7–7.0 |
| trans FA | <1.0 | <2.2 | 0.003 | 0.006 | ≥0.15 | ≥0.27 |
| EPA + DHA 3 | 250 mg | 0.250 | 0.057 | 0.048 | 22.8 | 19.2 |
| Cholesterol 4 | <300 mg | <0.300 | 0.19 | 0.20 | ≥65.1 | ≥67.2 |
1 FAO [46]. 2 EU [47]. 3 The upper level of EPA (C20:5n-3 icosapentaenoic acid) and DHA (C22:6n-3, docosahexaenoic acid) consumption should not exceed 2 g/day. EPA was detected in examined samples in trace amounts). 4 WHO [48].